AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21973199
Drug: Pravastatin monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin monotherapy
Trial: 18584924
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care treatment (generic education only) (n=23)
Trial: 10838741
Drug: Triple-drug therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple-drug therapy without change (group B)
Trial: 8255478
Drug: Tolcapone (Ro
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolcapone (Ro 40-7592) administered in combination with levodopa/carbidopa
Trial: 26997218
Drug: 250 mL
RxNorm normalized name: TPN Bag 250 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mL 20% mannitol and 1 L 0.9% saline orally at 20:00 hours on the day before and at 05:00 hours on the day of CE and 20 mL simethicone 30 min before CE
Trial: 22444242
Drug: Novel dose-response
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Novel dose-response models considering spatial distribution of radiation dose
Trial: 22444242
Drug: Minimising dose
RxNorm normalized name: homatropine hydrobromide Ophthalmic Solution [Minims Homatropine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimising dose to the lateral and cranial component of the human parotid gland
Trial: 20534288
Drug: Once-daily everolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily everolimus administration
Trial: 20534288
Drug: Twice-daily everolimus
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily everolimus regimen
Trial: 20534288
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (once-daily and twice-daily)
Trial: 16088114
Drug: 1,000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 IU ergocalciferol daily
Trial: 8754325
Drug: 240 mg
RxNorm normalized name: aspirin 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg slow release verapamil once daily
Trial: 1864092
Drug: Oral acyclovir,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral acyclovir, 800 mg 5 times daily
Trial: 6749352
Drug: Verapamil 120
RxNorm normalized name: verapamil 120 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil 120 mg three times a day for 6 months
Trial: 24995659
Drug: Classical GON
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Classical GON block with 10 mg dexamethasone + 40 mg lidocaine (5 mL volume)
Trial: 24995659
Drug: Subcompartmental GON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcompartmental GON block with 10 mg dexamethasone + 40 mg lidocaine + nonionic iodine contrast + saline (5, 10, or 15 mL volume)
Trial: 9428499
Drug: Intermediate dose
RxNorm normalized name: Prevotella intermedia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate dose systemic methotrexate (IV‐MTX) with IT‐MTX
Trial: 18520310
Drug: Copayment policy
RxNorm normalized name: Polivy
DrugBank: Polatuzumab vedotin (DB12240)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Copayment policy for prescription drugs
Trial: 16033298
Drug: Fixed-dose rosiglitazone/metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose rosiglitazone/metformin 8 mg/2g per day
Trial: 16033298
Drug: Metformin 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 3 g/day
Trial: 14709951
Drug: St. John's
RxNorm normalized name: St. john's wort
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: St. John's wort extract (255 to 285 mg, 900 microg hypericin content)
Trial: 11471516
Drug: Non-drug measures
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-drug measures
Trial: 9568701
Drug: Enalapril treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril treatment for 12 weeks
Trial: 19225403
Drug: 1‐mg/kg propofol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1‐mg/kg propofol
Trial: 19225403
Drug: 0.2‐mg/kg etomidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2‐mg/kg etomidate
Trial: 16782098
Drug: Cox‐2 inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cox‐2 inhibitor treatment
Trial: 11156863
Drug: 1 mg/d
RxNorm normalized name: Lyllana 0.1 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/d 17ss‐estradiol continuously plus 0.025 mg gestodene for 12 days every month (standard‐progestin group)
Trial: 11156863
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg 17ss‐estradiol plus 0.025 mg gestodene for 12 days every third month (low‐progestin group)
Trial: 9225834
Drug: Dextrose 5%
RxNorm normalized name: Dextrose 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose 5% 600 to 800 kcal.d‐1 plus recombinant human growth hormone (DX + rGH)
Trial: 24073815
Drug: Cognitive narrative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive narrative intervention (4 weekly 60-min sessions)
Trial: 20354500
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection in the blood cardioplegic solution
Trial: 20354500
Drug: 4 mmol/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mmol/L of L-arginine in the blood cardioplegic solution
Trial: 20354500
Drug: 6 mmol/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mmol/L of L-arginine in the blood cardioplegic solution
Trial: 16203878
Drug: Nonoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoperative treatment with immobilization in a below-the-elbow plaster cast (44 patients)
Trial: 10087407
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg progesterone b.i.d. by the vaginal route (Esolut, Angelini) starting on the day of oocyte pick up (Group A, n = 15)
Trial: 10087407
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg intramuscular progesterone once daily (Prontogest, Amsa) (Group B, n = 15)
Trial: 7608310
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg of moexipril
Trial: 7608310
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg of moexipril
Trial: 27840443
Drug: Focused shockwave
RxNorm normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Focused shockwave therapy (FSWT; 2000 impulses, 4 Hz, 0.4 mJ/mm2)
Trial: 27840443
Drug: Radial shockwave
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radial shockwave therapy (RSWT; 2000 impulses, 8 Hz, 5 bars + 2000 impulses, 8 Hz, 2.5 bars)
Trial: 27840443
Drug: Focused shockwave
RxNorm normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Focused shockwave therapy (FSWT)
Trial: 26406193
Drug: Radial shockwave
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radial shockwave therapy (RSWT)
Trial: 25402398
Drug: iDecide (interactive,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iDecide (interactive, Web-based, tablet computer-delivered tool)
Trial: 23146640
Drug: Slow IANB
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow IANB with 3.6 mL of 2% lidocaine with 1:200,000 epinephrine
Trial: 23146640
Drug: Rapid IANB
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid IANB with 3.6 mL of 2% lidocaine with 1:200,000 epinephrine
Trial: 18375320
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate (7%) (1.2 mL/kg)
Trial: 18375320
Drug: Saline (0.9%)
RxNorm normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline (0.9%) (1.2 mL/kg)
Trial: 15750756
Drug: Interferon alpha-2a
RxNorm normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alpha-2a plus ribavirin 1,000/1,200 mg
Trial: 15750756
Drug: Interferon alpha-2a
RxNorm normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alpha-2a plus ribavirin 600 mg
Trial: 3933617
Drug: Seven day
RxNorm normalized name: Sevenfact
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seven day course of amoxycillin 125 mg three times a day
Trial: 3933617
Drug: Two day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two day course of amoxycillin 750 mg twice a day
Trial: 31192975
Drug: Tigecycline 1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tigecycline 1.2 mg/kg every 12 hours for children 8-11 years and 50 mg every 12 hours for children 12 to <18 years
Trial: 18001407
Drug: omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omeprazole 20 mg b.i.d. + clarithromycin 500 mg b.i.d. + amoxicillin 1 g b.i.d. for 1 week
Trial: 18001407
Drug: pantoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pantoprazole 40 mg b.i.d. + clarithromycin 500 mg b.i.d. + amoxicillin 1 g b.i.d. for 1 week
Trial: 18001407
Drug: rabeprazole 20
RxNorm normalized name: RABEprazole 20 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rabeprazole 20 mg b.i.d. + clarithromycin 500 mg b.i.d. + amoxicillin 1 g b.i.d. for 1 week
Trial: 18001407
Drug: esomeprazole 40
RxNorm normalized name: esomeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: esomeprazole 40 mg b.i.d. + clarithromycin 500 mg b.i.d. + amoxicillin 1 g b.i.d. for 1 week
Trial: 15143718
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment with Chaihu Droplet pill (CHDP) and Huoxiang Zhengqi Droplet pill (HZDP) for 13 days
Trial: 9881239
Drug: Human insulin
RxNorm normalized name: Human insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Human insulin (group B, n = 46)
Trial: 9881239
Drug: Animal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Animal insulin (group A, n = 48)
Trial: 7674870
Drug: Choline bitartrate
RxNorm normalized name: Choline Bitartrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Choline bitartrate (2.43 g)
Trial: 2282973
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g ampicillin plus 1 g sulbactam, given intravenously every 6 h
Trial: 2282973
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g cefoxitin, given intravenously every 6 h
Trial: 6111570
Drug: Oxycodone compound
RxNorm normalized name: oxyCODONE compounding powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone compound (equivalent to 12.5 mg morphine)
Trial: 25433727
Drug: Hands-on gel
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hands-on gel phantom training
Trial: 23650124
Drug: Topical capsaicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical capsaicin 8% (Qutenza)
Trial: 23650124
Drug: Topical low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topical low-dose capsaicin 0.04% (active control)
Trial: 15464767
Drug: Sublingual misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual misoprostol (200 microg/tablet, 2 tablets)
Trial: 15464767
Drug: Intravenous methylergometrine
RxNorm normalized name: methylergometrine
DrugBank: Methylergometrine (DB00353)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous methylergometrine (200 microg, 1 ml)
Trial: 7820061
Drug: Splenectomy after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Splenectomy after complete response (CR) to alpha interferon (IFN) therapy
Trial: 7820061
Drug: Alpha interferon
RxNorm normalized name: Natural alpha interferon
DrugBank: Interferon alfa (DB05258)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha interferon (IFN) therapy
Trial: 2040042
Drug: Enalapril 20
RxNorm normalized name: enalapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 20 mg qd
Trial: 31583253
Drug: Trigonella foenum‐graecum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trigonella foenum‐graecum seed powder solution (25g orally twice a day for one month)
Trial: 28756607
Drug: Dralitem® (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dralitem® (200 mg/m2)
Trial: 28756607
Drug: Temodal® (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temodal® (200 mg/m2)
Trial: 15042607
Drug: Screening (serum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Screening (serum PSA measurement and digital rectal examination)
Trial: 8140488
Drug: Single 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 1 g dose of azithromycin
Trial: 8140488
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg doxycycline twice daily for seven days
Trial: 11225459
Drug: Ringer solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer solution
Trial: 30309406
Drug: ASPMCG solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASPMCG solution
Trial: 27581533
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg telmisartan/5 mg amlodipine/12.5 mg hydrochlorothiazide (T80/A5/H12.5)
Trial: 27581533
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg telmisartan/12.5 mg hydrochlorothiazide (T80/H12.5)
Trial: 12607205
Drug: Fluoxetine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (40 mg/day) plus misoprostol (500 mg/day)
Trial: 12607205
Drug: Indomethacine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacine (100 mg/day) plus misoprostol (500 mg/day)
Trial: 12607205
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus misoprostol (500 mg/day)
Trial: 1598427
Drug: Ticlopidine (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticlopidine (500 mg/day for 30 days)
Trial: 1598427
Drug: Nifedipine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (30 mg/day for 30 days)
Trial: 1598427
Drug: Control (healthy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (healthy volunteers without treatment)
Trial: 6144128
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg zimelidine each morning for 5 days
Trial: 6144128
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg temazepam 2 h after zimelidine
Trial: 30102413
Drug: Selumetinib (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selumetinib (75 mg twice daily) plus docetaxel
Trial: 23406027
Drug: Selumetinib (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selumetinib (75 mg twice daily)
Trial: 26932437
Drug: Neoadjuvant chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemoradiotherapy (CRT) using a moderate radiation dose weekly combined with carboplatin and paclitaxel followed by surgery
Trial: 8574252
Drug: Ethinyl estradiol
RxNorm normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ethinyl estradiol 30 micrograms and gestodene 75 micrograms (oral contraceptives)
Trial: 2150580
Drug: Danazol (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danazol (600 mg/day orally)
Trial: 758493
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of dihydroergotamine and heparin
Trial: 27402913
Drug: Mercaptopurine treatment
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mercaptopurine treatment
Trial: 27402913
Drug: Concurrent anti-TNF
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent anti-TNF therapy
Trial: 12821551
Drug: EP-guided therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EP-guided therapy
Trial: 11432797
Drug: Initial daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial daily dosing of 6 MU Interferon-alpha-2a daily for 12 weeks, then reduced to 6 MU three times weekly until week 12 and 3 MU three times weekly thereafter until month 12.
Trial: 11432797
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy with 5 MU Interferon-alpha-2b or 6 MU Interferon-alpha-2a three times a week for 12 months.
Trial: 9730559
Drug: Low-grade CMV
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-grade CMV infection (no treatment)
Trial: 7982253
Drug: Brodimoprim 200
RxNorm normalized name: brodimoprim 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brodimoprim 200 mg tablets once a day (400 mg on the first day as a loading dose)
Trial: 7982253
Drug: Cephalexin 500
RxNorm normalized name: cephalexin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalexin 500 mg tablets three times a day for 8 to 12 days
Trial: 808445
Drug: Topical disodium
RxNorm normalized name: BALSALAZIDE DISODIUM
DrugBank: Balsalazide (DB01014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical disodium cromoglycate (DSCG) 200 mg by enema twice daily and 100 mg orally three times daily
Trial: 30642293
Drug: Lanreotide depot/autogel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanreotide depot/autogel 120 mg every 4 weeks for 96 weeks
Trial: 25096818
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acids (DHA and EPA) - 2 MorDHA capsules per day for 14 months
Trial: 24199774
Drug: Treated tea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treated tea (600 mL of oolong tea treated by three Buddhist monks)
Trial: 24199774
Drug: Untreated tea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Untreated tea (600 mL of ordinary oolong tea)
Trial: 21593492
Drug: Daily presentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily presentation of macaroni and cheese meal for 1 week
Trial: 21593492
Drug: Once-weekly presentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly presentation of macaroni and cheese meal for 5 weeks
Trial: 17397033
Drug: 3 years
RxNorm normalized name: NanoVM 1-3 years
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 years of androgen suppression therapy (AST) plus external beam radiation therapy (RT)
Trial: 17397033
Drug: 6 months
RxNorm normalized name: leuprolide 45 mg/6 months intramuscular kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 months of androgen suppression therapy (AST) plus external beam radiation therapy (RT)
Trial: 12547878
Drug: Maggot therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maggot therapy
Trial: 10703801
Drug: Phenobarbital (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenobarbital (20 mg/kg)
Trial: 10703801
Drug: Phenobarbital (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenobarbital (20 mg/kg) plus three or more doses of diazepam
Trial: 30464372
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (thermal therapy)
Trial: 23804546
Drug: Actiponin (450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Actiponin (450 mg day(-1))
Trial: 22739693
Drug: 13-valent pneumococcal
RxNorm normalized name: Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine
DrugBank: Streptococcus pneumoniae type 14 capsular polysaccharide diphtheria CRM197 protein conjugate antigen (DB10289)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 13-valent pneumococcal conjugate vaccine (PCV13) coadministered with trivalent inactivated influenza vaccine (TIV)
Trial: 10376904
Drug: IV administration
RxNorm normalized name: IV Administration Set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV administration of metformin (25 mg/kg)
Trial: 10376904
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of metformin (25 mg/kg)
Trial: 10376904
Drug: Computer simulations
RxNorm normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Computer simulations of oral metformin (2 mg/kg every 12 hours)
Trial: 8901787
Drug: Iron supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplementation (15 mg/d) for 3 months
Trial: 6181653
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg femoxetine daily for 6 weeks
Trial: 6181653
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg desipramine daily for 6 weeks
Trial: 29326015
Drug: Subcutaneous enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous enoxaparin administered in the abdomen